RecruitingNCT06189092

Treatment of Low-flow Venous Malformations With Electrosclerotherapy. Prospective Observational Study

Trattamento Delle Malformazioni Venose a Basso Flusso Con l'Elettroscleroterapia. Studio Osservazionale Prospettico


Sponsor

Istituto Ortopedico Rizzoli

Enrollment

65 participants

Start Date

Oct 28, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Venous malformations (MVs) are congenital abnormalities of the central or periphery caused by developmental errors at different stages of embryogenesis. Histologically they are characterized by large, venous-like vascular spaces. Scleroembolization constitutes the most widespread method in the treatment of venous malformations allowing good results with low invasiveness. Currently, Bleomycin (and its derivatives) is among the most widely used sclerosing agents for slow-flowing vascular malformations (venous and lymphatic malformations) because of the low rate of local serious adverse events such as swelling, necrosis, and nerve injury compared with others.


Eligibility

Min Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bleomycin for people with vascular malformations. The study is currently recruiting participants at 1 location. People eligible for this study include aged 16 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBleomycin

Using electroporation to infuse bleomycin in the lesion


Locations(1)

Istituto Ortopedico Rizzoli

Bologna, Emilia-Romagna, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06189092


Related Trials